The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice

Medicine & Life Sciences

• Devazepide 76%
• Cholecystokinin Receptors 69%
• Cholesterol 35%
• Gallstones 27%
• Crystallization 23%
• Gallbladder Emptying 22%
• Intestinal Absorption 16%
• Bile 14%
• Gallbladder 10%
• Liver 7%
• Chylomicrons 6%
• Residual Volume 5%
• Gastrointestinal Diseases 5%
• Metabolic Diseases 5%
• Bile Acids and Salts 5%
• Inbred C57BL Mouse 4%
• Biological Availability 4%
• Meals 4%
• Phospholipids 4%
• Oral Administration 4%
• Therapeutic Uses 3%
• Fasting 3%
• Fats 3%
• Diet 3%
• Lipids 3%
• Clinical Trials 3%
• Animals 2%

Chemical Compounds

• Devazepide 100%
• Agent Interacting With Transmitter, Hormone or Drug Receptor 53%
• Cholesterol 43%
• Crystallization 10%
• Bile Salt 6%
• Bioavailability 4%
• Crystal Growth 4%
• Phospholipid 4%
• Metabolic 3%
• Pharmacological Metabolism 3%
• Lipid 3%
• Volume 2%